1383572-19-7

Cabazitaxel-d₉ is intended for use as an internal standard for the quantification of cabazitaxel by GC- or LC-MS. Cabazitaxel is a second generation semisynthetic taxane derived from 10-deacetylbaccatin III . It stabilizes microtubule assembly by reducing lag time for tubulin assembly (LT₅₀ = 100 nM) and the rate of cold-induced microtubule depolymerization (IC₅₀s = 100-250 nM) in vitro. Cabazitaxel inhibits proliferation of P388, HL-60, Calc18, and KB cells (IC₅₀s = 4-41 nM), as well as P-glycoprotein-expressing, drug-resistant versions of these cell lines (IC₅₀s = 16-414 nM). In vivo, cabazitaxel dose-dependently reduces tumor growth in docetaxel-susceptible N87 human gastric carcinoma and docetaxel-resistant UISO BCA-1 breast cancer mouse xenograft models. Formulations containing cabazitaxel have been used in combination with prednisone in the treatment of hormone-refractory metastatic prostate cancer.

Cabazitaxel-d9 is deuterium labeled Cabazitaxel. Cabazitaxel is a semi-synthetic derivative of the natural taxoid 10-deacetylbaccatin III with potential antineoplastic activity.

Store at -20°C

[1] Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. DOI:10.1177/1060028018797110
[2] Tai X, et al. Cabazitaxel and indocyanine green co-delivery tumor-targeting nanoparticle for improved antitumor efficacy and minimized drug toxicity. J Drug Target. 2016 Sep 9:1-29. DOI:10.1080/1061186X.2016.1233975
[3] Gdowski AS, et al. Bone-targeted cabazitaxel nanoparticles for metastatic prostate cancer skeletal lesions and pain. Nanomedicine (Lond). 2017 Sep;12(17):2083-2095. DOI:10.2217/nnm-2017-0190